The current PE ratio of CRSP can't be determined, as the TTM EPS of -$2.8 is negative. The last PE ratio of CRISPR Therapeutics AG, recorded in March 2022, was 15.16.
The PE ratio of CRISPR Therapeutics AG has averaged 34.33 over the last eight years. In the past eight years, CRSP's PE ratio peaked in the Jun 2020 quarter at 118.53, when the stock price was $73.49 and the EPS was $0.62. The lowest point was in the Sep 2017 quarter, when it reached 4.68 with a price of $17.87 and an EPS of $3.82.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | 15.25 | N/A |
2020 | N/A | N/A |
2019 | 49.52 | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
ORMP Oramed Pharmaceuticals Inc | 21.55 | $95.54M |
OLMA Olema Pharmaceuticals Inc | N/A | $349.52M |
OMER Omeros Corp | N/A | $597.46M |
OMGA Omega Therapeutics Inc | N/A | $46.34M |
ONVO Organovo Holdings Inc | N/A | $5.53M |
ORIC Oric Pharmaceuticals Inc | N/A | $579.35M |
CRSP CRISPR Therapeutics AG | N/A | $3.48B |
The current price to earnings ratio of CRSP can't be calculated, as its EPS of -$2.8 is negative.
Over the last 5 years, the average price to earnings ratio for CRSP stock is 42.11.
In the last eight years, the Jun 2020 quarter recorded the highest quarterly PE ratio at 118.53.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.